Opinion 10 Jul 2023 Five innovations to take RNA vaccines to the next level By Venkata Indurthi, PhD, chief scientific officer, Aldevron During the COVID-19 pandemic, the world turned to a previously unused vaccine technology to rapidly develop desperately needed vaccines, providing immunity to millions worldwide. These new vaccines made use of the body’s natural translational machinery, which turns mRNA encoding the SARS-Cov2 spike protein into an antigen that […] July 10, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 7 Jul 2023 The future of food: what’s behind the cell-cultured meat industry regulations? The first-ever lab-grown burger was created at Maastricht University in the Netherlands, and eaten at a news conference in London in 2013. While everyone who tried a bite had something different to say about the taste and texture of the meat, it was agreed that this could be the start of something big. The technology […] July 7, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 CytoMed Therapeutics receives US patent for CAR-Gamma Delta T-cell technology CytoMed Therapeutics Limited, a Singapore-based biopharma company focused on novel donor cell-based immunotherapies for the treatment of various cancers, has announced that its CAR-gamma delta T cell (CAR-γδ T cell) technology, which it has licensed from A*STAR, has been granted a patent by the US Patent and Trademark Office (USPTO). The patent covers technologies for […] July 7, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 7 Jul 2023Beyond Biotech podcast 53: Antibody-drug conjugates On the podcast this week, we have a conversation about antibody-drug conjugates with Pejvack Motlagh, who was recently announced as the chief medical officer at Mablink Bioscience. Mablink Bioscience Mablink Bioscience is a biotechnology company developing the next generation of an emerging class of cancer drugs, antibody-drug conjugates (ADCs). Mablink’s patented hydrophilic drug-linker technology, PSARLink, […] July 7, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 TolerogenixX expands trial and closes €12M financing TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, has announced that its phase IIb study in renal transplant patients has received the green light to initiate the B arm of the study. This arm consists of patients receiving minimal immune suppression […] July 7, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 FDA approves Alzheimer’s treatment Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use. The decision makes LEQEMBI the first and only approved treatment shown to reduce the rate of disease progression […] July 7, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 Swedish researchers look to peptides to destroy viruses A new study from Sweden shows how a type of peptide from a lactic acid bacterium destroys viruses, including coronavirus. The findings have resulted in a Swedish patent, with an international patent pending. “We’re hoping for a quick turnaround to allow this discovery to be utilised in antiviral treatments and as a complement to vaccine,” […] July 7, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 6 Jul 2023 The biggest private biotech investments in June 2023 The companies Upstream Bio, Alkeus Pharmaceuticals and Worg Pharmaceuticals bagged the biggest biotech investments in June 2023, with oncology and ophthalmology players in particular attracting the most funding rounds. Overall, more funding rounds took place in June 2023 than in May, and the U.S. healthcare sector once again attracted particularly big rounds. We’ve gathered the […] July 6, 2023 - 2 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2023 LIfT produces neutrophil-based cell therapy from iPSCs LIfT BioSciences has announced successful proof-of-concept production of its patented cancer-killing alpha neutrophils from induced pluripotent stem cells (iPSCs). The proof-of-concept using iN-LIfT, the company’s second-generation platform, which is derived from iPSCs (a type of cell that has been reprogrammed so it is capable of becoming any type of cell) has shown that the alpha […] July 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2023 Positive data from Sensorion hearing loss study Sensorion, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has reported further analysis from its Proof of Concept (POC) phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation. In June 19, Sensorion announced that in preliminary […] July 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2023 AstraZeneca non-small cell lung cancer drug meets primary endpoint Positive high-level results from AstraZeneca’s TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy. […] July 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2023 £100M LifeArc program aims to help people living with rare diseases LifeArc, a self-funded, non-profit medical research organization and charity, is launching a new program to invest more than £100 million ($127.2 million) by 2030 to deliver new breakthroughs to improve the lives of people living with a rare disease. The Rare Disease Translational Challenge will bring together researchers in rare disease with LifeArc to get […] July 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email